Rare Disease Report

Ibrutinib to Treat Chronic Graft Versus Host Disease

JANUARY 19, 2017
David Miklos, MD

David Miklos, MD of Stanford University talks about the use of ibrutinib in chronic graft versus host disease.


Miklos D, Cutler CS, Arora M, et al. Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. Presented at the 58th Annual ASH Meeting and Exposition; San Diego, CA; December 3-6, 2016.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.